- Home
- STRW vs UNCY Comparison
STRW vs UNCY Comparison
Compare STRW & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRW | UNCY |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 145.3M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STRW | UNCY |
|---|---|---|
| Price | $14.02 | $5.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.88 | ★ $25.67 |
| AVG Volume (30 Days) | 34.5K | ★ 2.6M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 5.26 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $154,999,000.00 | $675,000.00 |
| Revenue This Year | $8.52 | N/A |
| Revenue Next Year | $3.95 | $582.86 |
| P/E Ratio | $81.47 | ★ N/A |
| Revenue Growth | ★ 32.41 | N/A |
| 52 Week Low | $10.00 | $3.72 |
| 52 Week High | $14.27 | $8.74 |
Technical Indicators
Market Signals| Indicator | STRW | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 42.56 |
| Support Level | $12.59 | $5.28 |
| Resistance Level | N/A | $6.17 |
| Average True Range (ATR) | 0.26 | 0.40 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 73.97 | 67.23 |
Price Performance
Historical ComparisonAbout STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.